En Carta Diagnostics

En Carta Diagnostics develops rapid Point-of-Care (POC) molecular diagnostics kits using aptamers. Their initial focus is on Lyme disease, addressing the limitations of current antibody-based tests with a platform capable of early and accurate diagnosis. The technology has broader applications across various genetic, pathogenic, and veterinary indications.

Buy Funded Startups lists

Funding Round: Pre-Seed

Funding Amount: €1.5M

Date: 23-May-2024

Investors: CentraleSupélec Venture, a handful of high-profile business angels

Markets: Healthtech, Diagnostics, Biotechnology Research

HQ: Paris, France

Founded: 2022

Website: https://www.encarta.bio/

LinkedIn: https://www.linkedin.com/company/en-carta-diagnostics

Twitter:

Instagram: